Skip to main content

Advertisement

SpringerLink
Log in

The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

A Correction to this article was published on 05 June 2024

This article has been updated

Abstract

Objective

To clarify the epidemiologic characteristics and risk of other tumors in survivors of gynecological tumors.

Materials and methods

This is a retrospective study based on the Surveillance, Epidemiology, and End Results database (SEER).

Results

The morbidity of other malignant tumors in patients with gynecological cancer was 8.07%. The most common subsequent tumors are breast, lung, colorectal, thyroid, and bladder cancers. Taking the incidence rate of the general population as reference, the second tumor with the highest relative risk in patients with cervical cancer is vulvar cancer. Bladder cancer is the second tumor with the highest relative risk value both in patients with corpus and ovarian cancer. The median period from the diagnosis of the initial tumor to the diagnosis of the second tumor was 5 years. Most patients with other tumors following gynecological cancer showed worse prognosis than patients with gynecological tumors only. However, thyroid cancer following ovarian cancer is a protective factor in survival.

Conclusion

Patients with gynecological tumors have a significantly higher risk of malignant tumors in other systems compared to ordinary population. It is necessary to be vigilant against subsequent high-risk tumors and tumors with poor prognosis within 5 years of initial diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

Data availability is not applicable to this article as no new data were created in this study. The data for analysis was from SEER database and may be downloaded at https://seer.cancer.gov/data/.

Change history

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  PubMed  Google Scholar 

  2. Marth C, Landoni F, Mahner S, et al (2017) ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(4):72–83

  3. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  4. Emons G, Mustea A, Tempfer C (2020) Tamoxifen and endometrial cancer: a janus-headed drug. Cancers (Basel) 12(9):2535

    Article  CAS  PubMed  Google Scholar 

  5. Hu R, Hilakivi-Clarke L, Clarke R (2015) Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncol Lett 9:1495–1501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ignatov A, Ortmann O (2020) Endocrine risk factors of endometrial cancer: polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen. Cancers (Basel) 12(7):1766

    Article  CAS  PubMed  Google Scholar 

  7. Guo J, Zhang Y, Qian H et al (2019) The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet 300(5):1399–1404

    Article  CAS  PubMed  Google Scholar 

  8. National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/. [accessed October 8, 2020]

  9. Siegel RL, Miller KD, Jemal A et al (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30

    Article  PubMed  Google Scholar 

  10. Bhat-Nakshatri P, Kumar B, Simpson E et al (2020) Breast cancer cell detection and characterization from breast milk-derived cells. Cancer Res 80(21):4828–4839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Oudkerk M, Liu S, Heuvelmans MA et al (2021) Lung cancer LDCT screening and mortality reduction – evidence, pitfalls and future perspectives. Nat Rev Clin Oncol 18(3):135–151

    Article  PubMed  Google Scholar 

  12. Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26(12):1859–1864

    Article  CAS  PubMed  Google Scholar 

  13. Henderson NC, Rieder F, Wynn TA (2020) Fibrosis: from mechanisms to medicines. Nature 587(7835):555–566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. de Martel C, Plummer M, Vignat J, Franceschi S et al (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141(4):664–670

  15. Faber MT, Sand FL, Albieri V et al (2017) Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer 141(6):1161–1169

    Article  CAS  PubMed  Google Scholar 

  16. Wei F, Li M, Wu X et al (2018) The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: a population-based study. Int J Cancer 142(6):1244–1251

    Article  CAS  PubMed  Google Scholar 

  17. Bertoli HK, Thomsen LT, Iftner T, Dehlendorff C, et al (2020) Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: a population-based prospective cohort study. Gynecol Oncol 157(2):456–462

  18. Mitchell AJ, Chan M, Bhatti H et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174

    Article  PubMed  Google Scholar 

  19. Afrisham R, Paknejad M, Soliemanifar O et al (2019) The influence of psychological stress on the initiation and progression of diabetes and cancer. Int J Endocrinol Metab 17(1):e67400

    PubMed  PubMed Central  Google Scholar 

  20. Kruk J, Aboul-Enein BH, Bernstein J, et al (2019) Psychological stress and cellular aging in cancer: a meta-analysis. Oxid Med Cell Longev 1270397

  21. Schlumberger M, Leboulleux S (2021) Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 17(3):176–188

    Article  CAS  PubMed  Google Scholar 

  22. Rahman ST, McLeod DSA, Pandeya N et al (2019) Understanding pathways to the diagnosis of thyroid cancer: are there ways we can reduce over-diagnosis? Thyroid 29(3):341–348

    Article  CAS  PubMed  Google Scholar 

  23. Liu J, Xu T, Ma L et al (2021) Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer. Front Oncol 11:593479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Poppe K (2021) Management of endocrine disease: thyroid and female infertility: more questions than answers?! Eur J Endocrinol 184(4):123–135

    Article  Google Scholar 

  25. Zhang C, Xia G, Tsang BK (2011) Interactions of thyroid hormone and FSH in the regulation of rat granulosa cell apoptosis. Front Biosci 3:1401–1413

    Google Scholar 

  26. Cardenas C, Alvero AB, Yun BS et al (2016) Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer 23(9):411–422

    Article  Google Scholar 

  27. Gharwan H, Bunch KP, Annunziata CM (2015) The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer 22:339–363

    Article  Google Scholar 

  28. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–14

Download references

Acknowledgements

We thank SEER database for sharing the resource. The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.

Funding

Not applicable.

Author information

Author notes

  1. Jianbin Guo, Hao Wang and Xueke Zou authors contributed equally to this work.

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, 250021, Shandong, China

    Jianbin Guo

  2. Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1, Shuaifuyuan, Dongcheng District, 100730, Beijing, China

    Jianbin Guo, Roujie Huang & Shuo Liang

  3. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, No. 1, Shuaifuyuan, Dongcheng District, 100730, Beijing, China

    Hao Wang & Zhiyong Liang

  4. Department of Dermatology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, 250021, Shandong, China

    Xueke Zou

Authors
  1. Jianbin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xueke Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roujie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiyong Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuo Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhiyong Liang or Shuo Liang.

Ethics declarations

Conflict of interest

The authors report no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, J., Wang, H., Zou, X. et al. The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors. Arch Gynecol Obstet (2024). https://doi.org/10.1007/s00404-024-07497-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00404-024-07497-z

Keywords

Search

Navigation